Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.

Six CAR-T-cell therapies have been approved by the European Commission and the US FDA, and other T-cell therapies are being ...

Using real-world data, Song found that patients treated with CAR T-cell therapies had improved overall survival compared with ...

Blinatumomab in addition to standard chemotherapy improved pediatric patients with NCI standard-risk B-cell acute lymphoblastic leukemia survival outcomes.

The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...

The following is a summary of “REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial,” published in the December 2024 issue of Critical Care by Hohn et al.

T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce ...

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the ...

INR:3550. the daily life of the immortal king season 5 release date Breaking news! Chinese scientists reveal the mechani ...

Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Myelodysplastic Syndrome.

PRINCETON, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO) announces the commencement of its Rights Offering, previously detailed in our December 9, 2024 announcement ...